Related Experiment Video
Updated: Mar 31, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Mitochondrial dysfunction rather than mtDNA sequence mutation is responsible for the multi-drug resistance of small
Abstract:
Small cell lung cancer (SCLC) accounts for ~15% of all lung cancer cases, and chemotherapy has dramatically improved the survival rate of SCLC patients. Yet, the long-term survival rate of this cancer has not improved since multi-drug resistance (MDR) may emerge after chemotherapy. Mitochondrial DNA (mtDNA) mutation-related biological processes, such as energy metabolism and reactive oxygen species (ROS) production, have been considered to be associated with tumorigenesis and drug resistance. It was hypothesized and demonstrated, in the present study, that mitochondrial dysfunction is the reason for the occurrence and progression of SCLC. mtDNA from drug sensitive and drug insensitive cell lines (H446 and H446/CDDP) was sequenced and compared with the revised Cambridge reference sequence (rCRS). The results revealed that there was no difference in the mtDNA sequence from H446 and H446/CDDP cells, but several spot mutations were observed according to that of rCRs. Further evaluation on mitochondrial function revealed that H446 cells synthesized and secreted more lactic acid and ROS compared with that of H446/CDDP cells when challenged by the same dose of cisplatin (P>0.05). In addition, examination of the mitochondrial apoptotic pathway indicated that more Bax, cleaved caspase-3 and cleaved caspase-9 were expressed in H446 cells compared with that of H446/CDDP cells when stimulated by the same dose of cisplatin (P>0.05). In conclusion, the results of the present study revealed that mtDNA mutations were responsible for the tumorigenesis of SLCL, but not associated with the drug sensitivity of SCLC cell lines. On the other hand, varied mitochondrium content‑related mitochondrial dysfunction participated in the MDR of SCLC possibly by affecting the ROS-mediated mitochondrial apoptotic pathway.
Insights
Mitochondrial DNA mutations drive small cell lung cancer (SCLC) development. However, mitochondrial dysfunction, not mtDNA mutations, contributes to chemotherapy drug resistance in SCLC by impacting the reactive oxygen species-mediated apoptotic pathway.
Area of Science:
- Oncology
- Mitochondrial Biology
- Genetics
Background:
- Small cell lung cancer (SCLC) survival is limited by chemotherapy resistance.
- Mitochondrial DNA (mtDNA) mutations are implicated in tumorigenesis and drug resistance.
- Mitochondrial dysfunction is hypothesized to drive SCLC occurrence and progression.
Purpose of the Study:
- To investigate the role of mtDNA mutations in SCLC tumorigenesis.
- To determine the association between mtDNA and SCLC drug sensitivity.
- To explore the contribution of mitochondrial dysfunction to multidrug resistance (MDR) in SCLC.
Main Methods:
- Sequencing of mtDNA from drug-sensitive (H446) and drug-insensitive (H446/CDDP) SCLC cell lines.
- Comparison of mtDNA sequences with the revised Cambridge reference sequence (rCRS).
- Assessment of mitochondrial function, including lactic acid and reactive oxygen species (ROS) production, and analysis of the mitochondrial apoptotic pathway.
Main Results:
- No significant differences in mtDNA sequences were found between H446 and H446/CDDP cells, though spot mutations were observed relative to rCRS.
- H446 cells exhibited higher lactic acid and ROS synthesis than H446/CDDP cells upon cisplatin challenge.
- Increased expression of Bax, cleaved caspase-3, and cleaved caspase-9 was noted in H446 cells compared to H446/CDDP cells post-cisplatin stimulation.
Conclusions:
- mtDNA mutations are linked to SCLC tumorigenesis but not directly to drug sensitivity.
- Mitochondrial dysfunction, potentially due to varied mitochondrium content, contributes to SCLC multidrug resistance.
- The ROS-mediated mitochondrial apoptotic pathway is a key factor in SCLC drug resistance.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mitochondrial Membranes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

